| Filed On | Filing |
|---|---|
| 06 Nov 2026 |
8-K: Results of Operations and Financial Condition
Revenue Increased 10% Year Over Year, Led by 17% Commercial Channel Growth Including More Than 30% Growth in IntegrityTM Revenue |
| 29 Jul 2026 |
8-K: Results of Operations and Financial Condition
Commercial Channel Revenue Increased 17% to a Record $13.9 Million |
| 14 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
This FIFTH AMENDMENT TO CREDIT AGREEMENT, dated as of July 10, 2026 (this “Fifth Amendment”), is entered into among ANIKA THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), the Subsidiary Guarantors party hereto (if any), each ... |
| 23 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Anika Therapeutics, Inc. sets forth herein the terms of its 2017 Omnibus Incentive Plan. |
| 29 Apr 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target |
| 08 Jan 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
This Employment Agreement (“Agreement”) shall be effective as of February 1, 2026 between Anika Therapeutics, Inc., a Delaware corporation (the “Company”), and Steve Griffin (the “Executive”). |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth |
| 30 Jul 2025 |
8-K: Results of Operations and Financial Condition
Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025 |
| 30 Jul 2025 |
8-K: Regulation FD Disclosure
Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update |
| 24 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Anika Therapeutics, Inc. sets forth herein the terms of its 2017 Omnibus Incentive Plan. |
| 09 May 2025 |
8-K: Results of Operations and Financial Condition
Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 |
| 10 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On April 4, 2025, Anika Therapeutics, Inc. (the “Company”) announced the departure of Anne Nunes, Chief Operations Officer, effective April 25, 2025. |
| 12 Mar 2025 |
8-K: Results of Operations and Financial Condition
Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% |
| 11 Mar 2025 |
8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure
Execution of Previously Announced Plan Sharpens Focus on Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio |
| 31 Oct 2024 |
8-K: Results of Operations and Financial Condition
Updating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwinds |
| 31 Oct 2024 |
8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure
Company to Focus on Profitable Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio, Streamline Operations and Enhance Growth Profile |
| 08 Aug 2024 |
8-K: Results of Operations and Financial Condition
Expanded Regenerative Solutions portfolio with full market release of the Integrity™ Implant System, a hyaluronic acid (HA)-based scaffold for rotator cuff and other tendon repairs, generating significant market demand |
| 11 Jul 2024 |
8-K: Submission of Matters to a Vote of Security Holders
Anika Therapeutics, Inc., or the Company, held the 2024 Annual Meeting of Stockholders, or the Annual Meeting, on July 9, 2024. The board of directors of the Company, or the Board, solicited proxies for the Annual Meeting pursuant to the... |
| 28 May 2024 |
8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +1 more
This COOPERATION AGREEMENT (this “Agreement”) is made and entered into as of May 28, 2024, by and between Anika Therapeutics, Inc., a Delaware corporation (the “Company”), Caligan Partners LP, Caligan Partners Master Fund LP and David Jo... |
Loading...